224 related articles for article (PubMed ID: 26540491)
21. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
[TBL] [Abstract][Full Text] [Related]
22. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
[TBL] [Abstract][Full Text] [Related]
23. Comparative Effectiveness of Two Tiotropium Formulations: A Retrospective Cohort Study.
Spila-Alegiani S; Trotta F; Da Cas R; Rossi M; Venegoni M; Traversa G
COPD; 2018 Oct; 15(5):418-423. PubMed ID: 30822243
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy and safety of tiotropium Respimat in the treatment of chronic obstructive pulmonary disease: systematic review].
Cai HD; Hou J; Lyu YN; Xiong L; Lu MZ; Wu SL
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Aug; 40(8):596-603. PubMed ID: 28810313
[No Abstract] [Full Text] [Related]
25. Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease.
Keating GM
Drugs; 2014 Oct; 74(15):1801-16. PubMed ID: 25300412
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV
Calverley PMA; Mueller A; Fowler A; Metzdorf N; Wise RA
Ann Am Thorac Soc; 2018 Feb; 15(2):200-208. PubMed ID: 28957643
[TBL] [Abstract][Full Text] [Related]
27. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.
Verhamme KM; Afonso A; Romio S; Stricker BC; Brusselle GG; Sturkenboom MC
Eur Respir J; 2013 Sep; 42(3):606-15. PubMed ID: 23520322
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.
Dahl R; Engel M; Dusser D; Halpin D; Kerstjens HAM; Zaremba-Pechmann L; Moroni-Zentgraf P; Busse WW; Bateman ED
Respir Med; 2016 Sep; 118():102-111. PubMed ID: 27578478
[TBL] [Abstract][Full Text] [Related]
30. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.
Ichinose M; Fujimoto T; Fukuchi Y
Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446
[TBL] [Abstract][Full Text] [Related]
31. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators.
Halpin DM; Kaplan AG; Russell RK
Respir Med; 2017 Jul; 128():28-41. PubMed ID: 28610667
[TBL] [Abstract][Full Text] [Related]
32. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S
Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
Tang Y; Massey D; Zhong NS
Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
[TBL] [Abstract][Full Text] [Related]
34. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
35. Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.
Trotta F; Da Cas R; Rajevic M; Rossi M; Traversa G
BMJ Open; 2015 May; 5(5):e006619. PubMed ID: 26009573
[TBL] [Abstract][Full Text] [Related]
36. [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease].
Ma J; Zhou Z; Tang Y; Zhong N
Zhonghua Nei Ke Za Zhi; 2014 Dec; 53(12):964-8. PubMed ID: 25623564
[TBL] [Abstract][Full Text] [Related]
37. Tiotropium Respimat Soft Mist Inhaler versus HandiHaler to improve sleeping oxygen saturation and sleep quality in COPD.
Bouloukaki I; Tzanakis N; Mermigkis C; Giannadaki K; Moniaki V; Mauroudi E; Michelakis S; Schiza SE
Sleep Breath; 2016 May; 20(2):605-12. PubMed ID: 26407963
[TBL] [Abstract][Full Text] [Related]
38. Tiotropium HandiHaler in the treatment of COPD: a safety review.
Kesten S; Celli B; Decramer M; Leimer I; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2009; 4():397-409. PubMed ID: 20037679
[TBL] [Abstract][Full Text] [Related]
39. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD.
Hodder R; Pavia D; Lee A; Bateman E
Int J Chron Obstruct Pulmon Dis; 2011; 6():245-51. PubMed ID: 21814460
[TBL] [Abstract][Full Text] [Related]
40. Bronchodilator Effect of Tiotropium via Respimat
Ogasawara T; Sakata J; Aoshima Y; Tanaka K; Yano T; Kasamatsu N
Intern Med; 2017 Sep; 56(18):2401-2406. PubMed ID: 28824055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
